Abstract | PURPOSE OF REVIEW:
Glucocorticoids are used in the treatment of most rheumatic diseases, and are used chronically in up to 50% of cases of rheumatoid arthritis. The frequency of their use has in the past been incompletely supported by trial evidence of their benefit and by incomplete understanding of their mechanisms of action. The present review will examine significant recent publications relating to glucocorticoids of relevance to rheumatology RECENT FINDINGS: SUMMARY: Despite over 50 years of glucocorticoid use in rheumatology, basic science and clinical studies continue to yield intriguing new data. The quest for therapeutic agents with the beneficial effects of glucocorticoids but lacking their harmful effects is aided by this progress.
|
Authors | Eric F Morand |
Journal | Current opinion in rheumatology
(Curr Opin Rheumatol)
Vol. 19
Issue 3
Pg. 302-7
(May 2007)
ISSN: 1040-8711 [Print] United States |
PMID | 17414960
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antirheumatic Agents
- Cell Cycle Proteins
- Glucocorticoids
- Immediate-Early Proteins
- Receptors, Glucocorticoid
- Phosphoprotein Phosphatases
- Protein Phosphatase 1
- DUSP1 protein, human
- Dual Specificity Phosphatase 1
- Dusp1 protein, mouse
- Protein Tyrosine Phosphatases
|
Topics |
- Animals
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Arthritis
(drug therapy, metabolism)
- Arthritis, Experimental
(drug therapy, metabolism)
- Arthritis, Rheumatoid
(drug therapy, metabolism)
- Bone Density
(drug effects)
- Cell Cycle Proteins
(metabolism)
- Dual Specificity Phosphatase 1
- Glucocorticoids
(adverse effects, therapeutic use)
- Humans
- Immediate-Early Proteins
(metabolism)
- Inflammation
(drug therapy, metabolism)
- MAP Kinase Signaling System
(drug effects)
- Mice
- Phosphoprotein Phosphatases
(metabolism)
- Protein Phosphatase 1
- Protein Tyrosine Phosphatases
(metabolism)
- Receptors, Glucocorticoid
(drug effects)
|